320 related articles for article (PubMed ID: 26202431)
1. Reduced canine BRCA2 expression levels in mammary gland tumors.
Yoshikawa Y; Morimatsu M; Ochiai K; Ishiguro-Oonuma T; Wada S; Orino K; Watanabe K
BMC Vet Res; 2015 Jul; 11():159. PubMed ID: 26202431
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of BRCA2 and RAD51 in lymph node metastases of canine mammary adenocarcinomas.
Klopfleisch R; Gruber AD
Vet Pathol; 2009 May; 46(3):416-22. PubMed ID: 19176491
[TBL] [Abstract][Full Text] [Related]
3. Novel variations and loss of heterozygosity of BRCA2 identified in a dog with mammary tumors.
Yoshikawa Y; Morimatsu M; Ochiai K; Nagano M; Tomioka Y; Sasaki N; Hashizume K; Iwanaga T
Am J Vet Res; 2008 Oct; 69(10):1323-8. PubMed ID: 18828690
[TBL] [Abstract][Full Text] [Related]
4. Molecular cloning and tumour suppressor function analysis of canine REIC/Dkk-3 in mammary gland tumours.
Ochiai K; Watanabe M; Azakami D; Michishita M; Yoshikawa Y; Udagawa C; Metheenukul P; Chahomchuen T; Aoki H; Kumon H; Morimatsu M; Omi T
Vet J; 2013 Sep; 197(3):769-75. PubMed ID: 23732075
[TBL] [Abstract][Full Text] [Related]
5. Loss of p27 expression in canine mammary tumors and their metastases.
Klopfleisch R; Schütze M; Gruber AD
Res Vet Sci; 2010 Apr; 88(2):300-3. PubMed ID: 19748645
[TBL] [Abstract][Full Text] [Related]
6. Single nucleotide variation in exon 11 of canine BRCA2 in healthy and cancerous mammary tissue.
Hsu WL; Huang YH; Chang TJ; Wong ML; Chang SC
Vet J; 2010 Jun; 184(3):351-6. PubMed ID: 19944633
[TBL] [Abstract][Full Text] [Related]
7. Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy.
Thumser-Henner P; Nytko KJ; Rohrer Bley C
BMC Vet Res; 2020 Jan; 16(1):30. PubMed ID: 32005245
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of FOXP3 expression in canine mammary gland tumours.
Oh SY; Ryu HH; Yoo DY; Hwang IK; Kweon OK; Kim WH
Vet Comp Oncol; 2014 Mar; 12(1):20-8. PubMed ID: 22541038
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a PCR analysis method for canine BRCA2.
Yoshikawa Y; Morimatsu M; Ochiai K; Okuda K; Taoda T; Chikazawa S; Shimamura A; Omi T; Bonkobara M; Orino K; Watanabe K
BMC Res Notes; 2012 Apr; 5():173. PubMed ID: 22471976
[TBL] [Abstract][Full Text] [Related]
10. Expression patterns of the BRCA1 splicing variants in canine normal tissues and mammary gland tumors.
Sugiura T; Matsuyama S; Akiyosi H; Takenaka S; Yamate J; Kuwamura M; Aoki M; Shimada T; Ohashi F; Kubo K
J Vet Med Sci; 2007 Jun; 69(6):587-92. PubMed ID: 17611353
[TBL] [Abstract][Full Text] [Related]
11. Common germline haplotypes and genotypes identified in BRCA2 exon 11 of dogs with mammary tumours and histopathological analyses.
Maués T; El-Jaick KB; Costa FB; Araujo GEF; Soares MVG; Moreira AS; Ferreira MLG; Ferreira AMR
Vet Comp Oncol; 2018 Sep; 16(3):379-384. PubMed ID: 29512278
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of C5a receptor (CD88) mRNA in canine mammary tumors.
Hezmee MN; Kyaw-Tanner M; Lee JY; Shiels IA; Rolfe B; Woodruff T; Mills PC
Vet Immunol Immunopathol; 2011 Jan; 139(1):50-6. PubMed ID: 20846729
[TBL] [Abstract][Full Text] [Related]
13. Cloning and sequencing full length of canine Brca2 and Rad51 cDNA.
Ochiai K; Morimatsu M; Tomizawa N; Syuto B
J Vet Med Sci; 2001 Oct; 63(10):1103-8. PubMed ID: 11714026
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns of connexin 26 and connexin 43 mRNA in canine benign and malignant mammary tumours.
Gotoh H; Harada K; Suzuki K; Hashimoto S; Yamamura H; Sato T; Fukumoto K; Hagiwara H; Ishida T; Yamada K; Asano R; Yano T
Vet J; 2006 Jul; 172(1):178-80. PubMed ID: 16772144
[TBL] [Abstract][Full Text] [Related]
15. Expression of the PTEN tumor suppressor gene in malignant mammary gland tumors of dogs.
Kanae Y; Endoh D; Yokota H; Taniyama H; Hayashi M
Am J Vet Res; 2006 Jan; 67(1):127-33. PubMed ID: 16426222
[TBL] [Abstract][Full Text] [Related]
16. Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines.
Ahern TE; Bird RC; Bird AE; Wolfe LG
Am J Vet Res; 1996 May; 57(5):693-6. PubMed ID: 8723884
[TBL] [Abstract][Full Text] [Related]
17. Promoter mutation and reduced expression of BRCA1 in canine mammary tumors.
Qiu HB; Sun WD; Yang X; Jiang QY; Chen S; Lin DG
Res Vet Sci; 2015 Dec; 103():143-8. PubMed ID: 26679809
[TBL] [Abstract][Full Text] [Related]
18. Effects of the missense mutations in canine BRCA2 on BRC repeat 3 functions and comparative analyses between canine and human BRC repeat 3.
Yoshikawa Y; Ochiai K; Morimatsu M; Suzuki Y; Wada S; Taoda T; Iwai S; Chikazawa S; Orino K; Watanabe K
PLoS One; 2012; 7(10):e45833. PubMed ID: 23071527
[TBL] [Abstract][Full Text] [Related]
19. Establishment of primary mixed cell cultures from spontaneous canine mammary tumors: Characterization of classic and new cancer-associated molecules.
Gentile LB; Nagamine MK; Biondi LR; Sanches DS; Toyota F; Giovani TM; de Jesus IP; da Fonseca IIM; Queiroz-Hazarbassanov N; Diaz BL; Salles Gomes COM; Dagli MLZ
PLoS One; 2017; 12(9):e0184228. PubMed ID: 28945747
[TBL] [Abstract][Full Text] [Related]
20. Expression patterns of the erbB subfamily mRNA in canine benign and malignant mammary tumors.
Matsuyama S; Nakamura M; Yonezawa K; Shimada T; Ohashi F; Takamori Y; Kubo K
J Vet Med Sci; 2001 Sep; 63(9):949-54. PubMed ID: 11642281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
